Cargando…
The dark side of immunotherapy: pancreatic cancer
Since the journal Science deemed cancer immunotherapy as the “breakthrough of the year” in 2014, there has been an explosion of clinical trials involving immunotherapeutic approaches that, in the last decade - thanks also to the renaissance of the immunosurveillance theory (renamed the three Es theo...
Autores principales: | Mucciolo, Gianluca, Roux, Cecilia, Scagliotti, Alessandro, Brugiapaglia, Silvia, Novelli, Francesco, Cappello, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992483/ https://www.ncbi.nlm.nih.gov/pubmed/35582441 http://dx.doi.org/10.20517/cdr.2020.13 |
Ejemplares similares
-
The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer
por: Curcio, Claudia, et al.
Publicado: (2021) -
Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners
por: Cappello, Paola, et al.
Publicado: (2018) -
IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine
por: Roux, Cecilia, et al.
Publicado: (2021) -
The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021) -
Next generation of cancer immunotherapy calls for combination
por: Cappello, Paola, et al.
Publicado: (2017)